Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Personalized Treatments for Glaucoma Patients
share announcement

Personalized Treatments for Glaucoma Patients

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Ophthalmology".

Deadline for manuscript submissions: 20 September 2025 | Viewed by 2326

Special Issue Editor

Dr. Gloria Roberti

E-Mail Website
Guest Editor
IRCCS—Fondazione Bietti, Via Livenza, 3, 00198 Rome, Italy
Interests: glaucoma; cataract; visual field; medical treatment; surgical treatment

Special Issue Information

Dear Colleagues,

Personalized treatments for glaucoma patients involve tailoring interventions to meet the unique needs of each individual. These treatments consider factors such as the type and severity of glaucoma, the patient’s age, overall health, and lifestyle. Common approaches include the use of eye drops to lower intraocular pressure (IOP), laser therapy to improve fluid drainage, and surgical options for advanced cases. Regular monitoring and follow-up visits are crucial to assess treatment effectiveness and make necessary adjustments. The goal of personalized treatments is to preserve vision and enhance the quality of life for glaucoma patients.

The topics may include:

  • High intraocular pressure (IOP): Elevated IOP is a major risk factor for glaucoma development and progression. Managing and reducing IOP is a key focus of glaucoma treatment.
  • Optic nerve damage: The extent of optic nerve damage is an important consideration in determining the appropriate treatment approach. More advanced damage may require more aggressive interventions.
  • Visual field loss: The severity and progression of visual field loss play a role in determining the urgency and intensity of glaucoma treatment.
  • Cup-to-disc ratio: A larger cup-to-disc ratio, which indicates a larger area of optic nerve damage, may indicate a higher risk and require more aggressive treatment.
  • Medical conditions: Coexisting medical conditions, such as diabetes or cardiovascular disease, can complicate glaucoma treatment and may require additional considerations.
  • Previous eye surgeries or injuries: Past eye surgeries or injuries can affect the choice of treatment options and their effectiveness.
  • Post-surgical complications: The surgical treatment may cause transient or persistent hyphema (blood in the anterior chamber); intraocular pressure spikes or fluctuations; post-surgical hypotension; cataract formation, etc.
  • Allergic reactions or side effects from eye drops, such as redness, itching, or burning sensation, in addition to systemic side effects from oral medications, including respiratory issues, heart problems, or gastrointestinal disturbances.
  • Treatment of more aggressive and fast-progressive glaucoma, like PEXG or NVG.
  • Treatment of normal tension glaucoma.
  • The role of neuroprotection in glaucoma treatment.

Dr. Gloria Roberti
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • glaucoma
  • intraocular pressure (IOP)
  • optic nerve damage
  • visual field loss
  • ophthalmoscopy
  • angle closure glaucoma
  • open-angle glaucoma
  • primary glaucoma
  • secondary glaucoma
  • normal-tension glaucoma
  • pigmentary glaucoma

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 1608 KiB  
Article
Short-Term Safety and Efficacy of PreserFlo™ Microshunt in Patients with Refractory Intraocular Pressure Elevation After Dexamethasone Implant Intravitreal Injection
by Leonie Bourauel, Michael Petrak, Frank G. Holz, Karl Mercieca and Constance Weber
J. Clin. Med. 2025, 14(2), 507; https://doi.org/10.3390/jcm14020507 - 14 Jan 2025
Viewed by 777
Abstract
Background: The PreserFlo™ MicroShunt (PFMS) is a bleb-forming device considered to be less invasive than traditional glaucoma surgery such as trabeculectomy. This study evaluates the 1-year success rates as well as safety profile of PFMS in patients having high intraocular pressure (IOP) [...] Read more.
Background: The PreserFlo™ MicroShunt (PFMS) is a bleb-forming device considered to be less invasive than traditional glaucoma surgery such as trabeculectomy. This study evaluates the 1-year success rates as well as safety profile of PFMS in patients having high intraocular pressure (IOP) and/or glaucoma refractory to drop therapy with a history of prior intravitreal dexamethasone therapy. Methods: A total of 16 eyes after PFMS implantation due to elevated IOP after intravitreal dexamethasone implant (DEX-I) administration were included in this retrospective cohort study. Success rates and secondary outcomes were evaluated. Results: Qualified and complete success rates at 12 months, respectively, were 14/16 and 12/16 eyes for criterion A, 13/16 and 11/16 eyes for B, 13/16 and 11/16 eyes for C, and 6/16 and 6/16 eyes for D. The overall mean (range) preoperative IOP decreased from 27 (16–38) mmHg to 13 (10–17) mmHg at 12 months. BCVA was not significantly different up to 12 months (p = 0.63). The preoperative mean (range) number of medications decreased from 3.56 (2–4) to 0.31 (0–3) at 12 months. One eye underwent needling twice, and two eyes were revised surgically. One patient needed replacement of the PFMS. There were no hypotony-related complications. Conclusions: The PFMS is an effective surgical option for patients with steroid-induced IOP elevation. It demonstrates satisfactory short-term success rates, a reduced need for pressure-lowering eye drops, an excellent safety profile with minimal postoperative care, and a low complication rate. Additional interventions such as needling or revisions were infrequently necessary. However, PFMS may not be the ideal choice for cases requiring a low target pressure (≤12 mmHg). Full article
(This article belongs to the Special Issue Personalized Treatments for Glaucoma Patients)
►▼ Show Figures

Figure 1

10 pages, 500 KiB  
Article
Intraocular Pressure Changes in Non-Surgical Eyes of Patients Admitted for Glaucoma Surgery
by Suguru Kubota, Soichiro Shimomine, Yoichi Kadoh and Masaki Tanito
J. Clin. Med. 2024, 13(15), 4511; https://doi.org/10.3390/jcm13154511 - 1 Aug 2024
Viewed by 1017
Abstract
(1) Background: In glaucoma patients, it is observed that intraocular pressure (IOP) in non-surgical eyes decreases during hospitalization, but detailed data have not been reported. This study aimed to examine changes in IOP in the non-surgical eyes of patients admitted for glaucoma [...] Read more.
(1) Background: In glaucoma patients, it is observed that intraocular pressure (IOP) in non-surgical eyes decreases during hospitalization, but detailed data have not been reported. This study aimed to examine changes in IOP in the non-surgical eyes of patients admitted for glaucoma surgery. (2) Methods: This retrospective study included 487 patients (254 males, 233 females). Statistical analysis was performed separately for groups that were and were not under medication treatment. (3) Results: In non-surgical eyes, the difference in IOP between admission and discharge was −1.6 ± 4.8 mmHg (95% confidence interval (CI), −2.1 to −1.2; p < 0.0001) with a significant decrease in the medication group (n = 414), while it was −0.6 ± 4.8 mmHg with no significant change observed (95% confidence interval (CI), −1.7 to 0.57; p = 0.33) in the non-medication group (n = 73). Multiple regression analysis of the medication group showed that IOP at admission (p < 0.0001) and older age (p = 0.03) were associated with the reduction or the rate of reduction in IOP. (4) Conclusions: IOP in the non-surgical eyes of patients admitted for glaucoma surgery with medication decreased during hospitalization. The reduction was more pronounced in individuals with higher IOP at admission and in older patients. It is possible that improved medication adherence contributes to the lowering of IOP. Full article
(This article belongs to the Special Issue Personalized Treatments for Glaucoma Patients)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop